Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in lymphatic endothelial cells | 0.75 |
| chemistry Open Targets | compounds already reach it: dipyridamole, pentoxifylline | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 6 Parkinson's papers of 242 | 0.74 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 3590
Sealed predictions
- PDE2A in dopamine neurons, braak+0.10 (p 0.807) → -0.27 (p 0.487)receipt 3598
Swarm cases
receipt 3598: PDE2A in dopamine neurons, braak
- power
- full sample -0.17 (p 0.509, n 18), 95% CI -0.59 to +0.33. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.14 (p 0.579, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.13 (p 0.597, n 18). could be the mix.
- skeptic
- leave-one-out range -0.26 to -0.06, sign flips 0; without severely affected donors -0.17 (p 0.509, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PDE2A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts